Quantum BioPharma QNTM 深 沪
交易中 10-20 10:56:57 美东时间
2.49
+0.080
+3.32%
华盛通- 最 高2.50
- 今 开2.42
- 成交量 4764股
- 最 低 2.42
- 昨 收 2.41
- 总市值 2013.79万
- 52周最高 12.42
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 2.07
- 委 比 75.00%
- 总股本 808.75万
- 历史最高 910.00
- 量 比 0.22
- 振 幅 3.32%
- 历史最低 2.07
- 每 手 1
- 风险率 2.78%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Top Wall Street Forecasters Revamp Thermo Fisher Scientific Expectations Ahead Of Q3 Earnings
Thermo Fisher Scientific Inc. (NYSE:TMO) will release its third quarter earnings report before the opening bell on Wednesday, Oct. 21. Analysts expect the Waltham, Massachusetts-based company to report quarterly earnings of $6.40 per share, up from $5.79 per share in the year-ago period. The consens...
今天 18:45
EXCLUSIVE: Thermo Fisher To Support Quantum Biopharma in Progressive Multiple Sclerosis Drug Trial
Quantum BioPharma Ltd. (NASDAQ:QNTM) on Tuesday said it is partnering with the clinical research division of Thermo Fisher Scientific Inc. (NYSE:TMO) to launch a Phase 2 clinical trial for its multiple sclerosis treatment, Lucid-MS. The companies signed a Study Start-Up Agreement, marking a major de...
10-06 17:48
Quantum BioPharma Signs Contract with Thermo Fisher Scientific’s Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis
Quantum BioPharma Ltd. has entered into a Study Start-Up Agreement with Thermo Fisher Scientific to implement a Phase 2 clinical trial for Lucid-MS, a novel neuroprotective therapy targeting progressive multiple sclerosis (MS). The trial, which is randomized, double-blind, and placebo-controlled, will evaluate the efficacy, safety, and tolerability of Lucid-MS, focusing on clinical and radiological endpoints relevant to disease progression. Lucid...
10-06 10:00
Quantum BioPharma’s Licensee Unbuzzd Wellness Announces Appointment Of Michael Zapolin As CEO
Quantum BioPharma Ltd. (NASDAQ:QNTM) (FRA: 0K91) ("Quantum BioPharma"), today announced its licensee – Unbuzzd Wellness Inc. (the "Company" or "Unbuzzd"), the company behind unbuzzd™ ("unbuzzd") — the scientifically-proven and game-changing beverage proven to accelerate alcohol metabolism, restore m...
09-24 20:02
Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO
Unbuzzd Wellness Inc., a licensee of Quantum BioPharma Ltd., appoints Michael Zapolin as CEO to oversee its listing on a stock exchange and nationwide rollout in the U.S. Zapolin, a seasoned entrepreneur and investor, aims to expand the company's market presence. Unbuzzd, a scientifically-proven beverage, accelerates alcohol metabolism, reduces hangover symptoms, and restores mental clarity. Backed by a peer-reviewed clinical study, the product i...
09-24 12:00
Quantum BioPharma reports Q4 results
Quantum BioPharma press release (QNTM): Q4 As of the date of filing, the Company had reduced trade and other payables by approximately 50%, from $4.1 million on December 31, 2025, to $2.0 million, re...
09-18 04:53
Quantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials
Quantum BioPharma Ltd. (NASDAQ: QNTM) has received FDA clearance to launch a phase 2 trial for Lucid-MS, a first-in-class drug designed to protect and potentially rebuild the myelin sheath in multiple sclerosis patients. This marks the first time a drug targeting this mechanism will be tested in humans, addressing a critical gap in MS treatment options. Lucid-MS aims to prevent and reverse myelin degradation, offering hope to nearly 1 million peo...
09-11 12:30
美股大行评级 | Affirm、GitLab获多家大行上调目标价；Attovia获大摩、花旗首予买入评级
今日重点评级关注：杰富瑞：维持拜玛林制药"买入"评级，目标价从104美元升至105美元；RBC Capital：维持Shift4 Payments"跑赢大市"评级，目标价从63美元升至67美元
09-01 08:37
Rodman & Renshaw Initiates Coverage On Quantum BioPharma with Buy Rating, Announces Price Target of $8
Rodman & Renshaw analyst Michael King initiates coverage on Quantum BioPharma (NASDAQ:QNTM) with a Buy rating and announces Price Target of $8.
09-01 01:00
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Draws ‘Buy’ Rating on Lucid-MS Potential
Austin, Texas, United States, August 31st, 2026, FinanceWire Disseminated...
09-01 00:30
